139 related articles for article (PubMed ID: 38382744)
21. Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.
Spekhorst LS; van den Reek JMPA; Knulst AC; Röckmann H
Allergy; 2019 Jun; 74(6):1185-1187. PubMed ID: 30593687
[No Abstract] [Full Text] [Related]
22. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.
Maurer M; Schütz A; Weller K; Schoepke N; Peveling-Oberhag A; Staubach P; Müller S; Jakob T; Metz M
J Allergy Clin Immunol; 2017 Sep; 140(3):870-873.e5. PubMed ID: 28389391
[No Abstract] [Full Text] [Related]
23. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
Belbezier A; Boccon-Gibod I; Bouillet L
Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
[No Abstract] [Full Text] [Related]
24. New treatments for chronic urticaria.
Kolkhir P; Altrichter S; Munoz M; Hawro T; Maurer M
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):2-12. PubMed ID: 31446134
[TBL] [Abstract][Full Text] [Related]
25. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
[No Abstract] [Full Text] [Related]
26. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
Hayama K; Fujita H; Asai-Sato M; Kawana K; Terui T
Eur J Dermatol; 2021 Feb; 31(1):100-101. PubMed ID: 33459258
[No Abstract] [Full Text] [Related]
28. Case of postural urticaria in a 14-year-old girl.
Gabrielli S; Le M; Netchiporouk E; Ben-Shoshan M
BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34711626
[TBL] [Abstract][Full Text] [Related]
29. Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).
Casale TB; Murphy TR; Holden M; Rajput Y; Yoo B; Bernstein JA
J Allergy Clin Immunol Pract; 2019; 7(7):2487-2490.e1. PubMed ID: 31034999
[No Abstract] [Full Text] [Related]
30. Successful treatment of four types of chronic urticaria with anti-IgE omalizumab in the same patient.
Nettis E; Di Leo E; Calogiuri G; Foti C; Macchia L
Ann Allergy Asthma Immunol; 2019 Mar; 122(3):336-337. PubMed ID: 30529714
[No Abstract] [Full Text] [Related]
31. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
[No Abstract] [Full Text] [Related]
32. Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.
Tonacci A; Nettis E; Asero R; Rossi O; Tontini C; Gangemi S
Eur Ann Allergy Clin Immunol; 2020 May; 52(3):100-103. PubMed ID: 32108461
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
Cho YT; Fu KT; Yang CW; Chu CY
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
[No Abstract] [Full Text] [Related]
34. Risk calculator of the clinical response to antihistamines in chronic urticaria: Development and internal validation.
Sánchez J; Jaimes F; García E; Zakzuk J; Cardona R; Velasquez M
PLoS One; 2024; 19(2):e0295791. PubMed ID: 38394074
[TBL] [Abstract][Full Text] [Related]
35. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
Farrah G; Stevenson B; Lie K; Brusch A
Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
[TBL] [Abstract][Full Text] [Related]
36. Omalizumab for chronic urticaria in children younger than 12 years.
Al-Shaikhly T; Rosenthal JA; Ayars AG; Petroni DH
Ann Allergy Asthma Immunol; 2019 Aug; 123(2):208-210.e2. PubMed ID: 31082483
[No Abstract] [Full Text] [Related]
37. Predictors of treatment response in chronic spontaneous urticaria.
Fok JS; Kolkhir P; Church MK; Maurer M
Allergy; 2021 Oct; 76(10):2965-2981. PubMed ID: 33539587
[TBL] [Abstract][Full Text] [Related]
38. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
[TBL] [Abstract][Full Text] [Related]
39. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria.
Bae Y; Kang SH; Park JO; Park GH; Choi JH
Allergol Int; 2020 Apr; 69(2):304-306. PubMed ID: 31767272
[No Abstract] [Full Text] [Related]
40. Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response.
Yu M; Terhorst-Molawi D; Altrichter S; Hawro T; Chen YD; Liu B; Song XT; Zhao ZT; Maurer M
Clin Exp Allergy; 2021 May; 51(5):730-734. PubMed ID: 33522024
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
